Ball et al 1 elegantly identified functional differences in response to L-and T-Ca channel blockade based on vessel size. The authors suggest that combined L and T calcium channel blockers (CCBs) may have additional therapeutic benefits over conventional L-channel blockers. This hypothesis deserves further investigation.
Is Combined L-and T-Channel Blockade Better Than L-Channel Blockade in Therapy?
To the Editor:
Ball et al 1 elegantly identified functional differences in response to L-and T-Ca channel blockade based on vessel size. The authors suggest that combined L and T calcium channel blockers (CCBs) may have additional therapeutic benefits over conventional L-channel blockers. This hypothesis deserves further investigation.
Differential distribution of L-and T-type channels in the glomerular circulation is illustrated by a predominant dilatation of afferent arteriole by nifedipine, whereas efonidipine dilates both afferent and efferent arterioles. 2 Efonidipine consistently reduces proteinuria in hypertensive patients with renal impairment. However, other clinical data show that cilnidipine, a L-N-type CCB, is renoprotective in diabetic nephropathy 3 and that lacidipine, a L-type blocker, preserves renal graft function in cyclosporine-treated recipients. 4 Hemodynamic properties of CCBs are classically related to arteriolar vasodilation. 2 Therapeutic regimens of CCBs evoke a reduction of blood pressure more pronounced in hypertensive than in normotensive patients. In spontaneously hypertensive rat vessels, this has been attributed to upregulation of Ca L channels and the increase of their affinity for CCBs. The latter has been related to a higher proportion of inactivated Ca channels because of the lower resting membrane potential of spontaneously hypertensive rat vessels compared with Wistar-Kyoto vessels. The ratio of affinity between the open and inactivated states of Ca L channels in arteries is varying among dihydropyridines, accounting for their vascular selectivity, an important parameter for their therapeutic effectiveness. 2 Other properties discussed elsewhere modulate CCB therapeutic efficacy, eg, interaction with the L-arginine-NO pathway, prevention of the overproduction of endothelin-1 in vessel walls, antioxidant effect, and cardiovascular structural changes during long-term therapy. 5 Ball et al 1 studied the peak effect of endothelin-1. Prolonged exposure of various vessels, including isolated human coronary arteries, to threshold doses of endothelin-1 enhances the frequency opening of Ca L channels, inducing the strengthening of vasoconstrictor action that is abolished by nanomolar concentrations of L-type CCBs such as nisoldipine. 2 Analysis of the inhibition by various CCBs of the long-drawn-out effect of endothelin-1 in microvessels examined by Ball et al 1 should enlarge information on the therapeutic mode of action of CCBs.
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